Yet, with GLIMS you get the most advanced information management system at your fingertips. GLIMS is compliant with all national legislation – pricing, invoicing, accounting, VAT – offering you pure peace of mind.You can even customise them for specific users! GLIMS is configurable, so you can freely define content of screens and reports.GLIMS can be expanded to other, on- or off-site labs, simply and without fuss.GLIMS is multi-lingual within a single database.The solution is used by over 15,000 people across 17 countries in 10 different languages, making it Europe’s most widely-used laboratory information system.īecause it is extremely flexible to the specific needs of your laboratory: GLIMS can be used in an extremely diverse range of laboratory disciplines: haematology, bacteriology, clinical chemistry, blood transfusions, serology, immunology, toxicology, microbiology, epidemiology, virology, clinical trials, veterinary. GLIMS is a comprehensive automation system for order-entry, instrument communication, results processing and validation, quality control, results communication, reconciliation and invoicing, payment follow-up and statistics. The heart of our solutions portfolio is GLIMS. Mean age (years, SD) 65.6 ( 21.2) <.GLIMS: The most widely-used laboratory information system in Europe

Variable All Periods n = 1011 Outsourced) n = 353

Prescriptions of Oseltamivir When Influenza Molecular Testing (Xpertįlu/RSV XC Assay) was Outsourced or Performed Onsite 24/7 Patients Characteristics, Molecular Assay Results, and Oseltamivir prescriptions associated with a positive assay are indicated in blue, and those with a negative assay are indicated in red. Time between results of Xpert Flu/RSV XC PCR Assay and dispense of the first dose of oseltamivir for the 2 periods.

In conclusion, because rapid molecular assays for influenza viruses are now available, they should be implemented as point-of-care testing as close as possible to emergency rooms for a more accurate prescription of antiviral drugs.Ĭaption: Figure 1. In 2020, the issue is different because the results of PCR-based assays are reliable and can be available within a few hours. However, these recommendations were published in 2011 and focused on the antigen-based diagnostic tests, known to have low sensitivity. The CDC recommends that patients with severe respiratory symptoms receive empirical influenza antiviral treatment despite a negative rapid influenza test result. Dugas et al suggested a strategy including a polymerase chain reaction (PCR)-based diagnostic test to initiate antiviral treatment for patients who met the Centers for Disease Control and Prevention (CDC) criteria. Trabattoni et al compared the impact of another rapid molecular diagnosis test (Alere i Influenza A and B Assay) when it was performed in the clinical ward or in the laboratory, and they did not find any difference in oseltamivir prescriptions. It is noteworthy that 3 studies were based on antigen-based diagnosis tests, which are known for their poor sensitivity. Few studies have evaluated the impact of influenza diagnostic testing on oseltamivir prescriptions.

Glims mips